IL9 and asthma: Therefore, a randomized, placebo-control, double-blind, multicenter, parallel-group study on an anti-IL-9 monoclonal Ab in patients with uncontrolled moderate-to-severe asthma was performed in 2013; however, no significant improvements in predicted FEV1 % were obtained [132].